Anemia, Author Interviews, Kidney Disease, Pharmacology, Stanford / 16.01.2017
Novel Oral Iron Formulation Can Correct Anemia in Non-Dialysis CKD
MedicalResearch.com Interview with:
Dr. Glenn M. Chertow, MD
Professor Medicine, Nephrology
Stanford University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Iron deficiency is common in persons with moderate to advanced (non-dialysis-dependent) chronic kidney disease (CKD), for a variety of reasons. Conventional iron supplements tend to be poorly tolerated and of limited effectiveness. In earlier studies of patients treated with ferric citrate for its effect as a phosphate binder, we saw increases in transferrin saturation and ferritin (markers of iron stores) and hemoglobin and hematocrit (the “blood count”). Therefore, we thought we should test the safety and efficacy of ferric citrate specifically for the treatment of iron deficiency anemia (IDA).
With respect to the key findings, more than half (52%) of patients treated with ferric citrate experienced a sizeable (>=1 g/dL) increase in hemoglobin over the 16-week study period compared to fewer than one in five (19%) patients treated with placebo. Rates of adverse events (“side effects”) were similar to placebo; diarrhea in some patients and constipation in others were the most common. There were also favorable effects of ferric citrate on laboratory metrics of bone and mineral metabolism.
(more…)